Effect of rituximab in secondary progressive multiple sclerosis
A prospective pilotstudy of immunological and radiological effects of intrathecal rituximab in patients with secondary progressive multiple sclerosis
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Change in spinal fluid immune respons after 1 and 3 month
Other measures (1)
Safety (Adverse events)
Safety
Who could take part
Progressive MS
Show the full criteria
Inclusion criteria
Inclusion: Clinical definate multiple sclerosis Exclusion: Pregnancy and lactation
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The aim of this study is to investigate the safety of intrathecal administered Rituximab to patients with secondary progressive multiple sclerosis, based upon analysis of the intrathecal and periferal immune response.
Loading reviews and guidelines…
Related trials
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cel
Phase 1 / Phase 2 · Not yet recruiting
Still running
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multi
Phase 1 · Paused
Still running
- The Effect of Rituximab on Cognitive and Hand Functions in Secondary P
Phase 2 · Recruiting
Still running
- Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With
Completed
No results found
- Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Completed
No results found
- A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Infla
Phase 4 · Withdrawn
Stopped
History
Started
Apr 2013